MG-Lin1

MG-Lin1 (0.1-100 μM; 24 h) potently enhances the activity of let-7 in PA-1 ovarian cancer cells, reducing the normalized luciferase intensity by 50% after 24 h of incubation at a concentration of 0.1 μM^[1].
MG-Lin1 (0.01-10 μM; 48 h) induces proteasome-dependent degradation of Lin28 in PA-1 ovarian cancer cells, with a degradation rate of 66% after treatment at 1 μM for 48 h, and its DC₅₀ is approximately 0.7 μM^[1].
MG-Lin1 (1-10 μM; 48 h) significantly increases the abundance of let-7c miRNA in PA-1 ovarian cancer cells, with the abundance elevated by more than 2-fold after treatment at 10 μM for 48 h^[1].
MG-Lin1 (10 μM; 48 h) reduces the mRNA levels of oncogenic KRAS and PDK1 in PA-1 ovarian cancer cells; after incubation at 10 μM for 48 h, the level of KRAS decreases to approximately 60% of that in the vehicle control group, and the level of PDK1 decreases to approximately 35% of that in the vehicle control group^[1].
MG-Lin1 (10 μM; 72 h) reduces the migration capacity of PA-1 ovarian cancer cells by 55% after incubation at a concentration of 10 μM for 72 h^[1].
MG-Lin1 (10 μM; 48 h) more effectively increases the abundance of let7-c in JAR cells compared with other tested degraders^[1].
MG-Lin1 (1 μM; 24 h) reduces the mRNA expression levels of KRAS and PDK1 in PA1 cells^[1].
MG-Lin1 (48 h) reduces the KRAS protein level in JAR cells to 66% of that in the vehicle control group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.